TY - JOUR
AU - Barry Fine
AU - Gordana Vunjak-Novakovic
AB - We provide here an historical context of how studies utilizing engineered human cardiac muscle can complement and in some cases substitute animal and cell models for studies of disease and drug testing. We give an overview of the development of animal models and discuss the ability of novel human tissue models to overcome limited predictive power of cell culture and animal models in studies of drug efficacy and safety. The in vitro generation of cardiac tissue is discussed in the context of state of the art in the field. Finally we describe the assembly of multitissue platforms for more accurate representation of integrated human cardiac physiology and consider the advantages of in silico drug trials to augment our ability to predict drug–drug and organ–organ interactions in humans.
BT - ACS Biomaterials Science & Engineering
DA - 2017-09-11
DO - 10.1021/acsbiomaterials.6b00662
IS - 9
N2 - We provide here an historical context of how studies utilizing engineered human cardiac muscle can complement and in some cases substitute animal and cell models for studies of disease and drug testing. We give an overview of the development of animal models and discuss the ability of novel human tissue models to overcome limited predictive power of cell culture and animal models in studies of drug efficacy and safety. The in vitro generation of cardiac tissue is discussed in the context of state of the art in the field. Finally we describe the assembly of multitissue platforms for more accurate representation of integrated human cardiac physiology and consider the advantages of in silico drug trials to augment our ability to predict drug–drug and organ–organ interactions in humans.
PY - 2017
SP - 1884
EP - 1897
T2 - ACS Biomaterials Science & Engineering
TI - Shortcomings of Animal Models and the Rise of Engineered Human Cardiac Tissue
UR - https://doi.org/10.1021/acsbiomaterials.6b00662
VL - 3
Y2 - 2023-02-02
ER -